BACKGROUND: Chronic anticoagulation is recommended in patients with hypertrophic cardiomyopathy (HCM) and atrial fibrillation (AF). Non-vitamin K antagonist oral anticoagulants (NOACs) are an alternative to warfarin, but there are limited data to support their use in patients with HCM and AF. We sought to compare thromboembolic events, bleeding, and mortality between NOAC and warfarin in patients with HCM and AF.
Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia in the general population, 1 and stroke prevention is the principal management priority in patients with AF, given its association with a fivefold increase in stroke risk. [1] [2] [3] Patients with hypertrophic cardiomyopathy (HCM) have a fourfold to sixfold greater likelihood of developing AF compared with the general population. [4] [5] [6] [7] AF is the most common arrhythmia in HCM and has been known to be associated with a high risk of stroke and systemic embolic events as well as heart failure-related mortality. 4, 5, 7 Currently, the congestive heart failure, hypertension, age $75 (doubled), diabetes mellitus, prior stroke or transient ischemic attack (doubled), vascular disease, age 65 to 74, female (CHA 2 DS 2 -VASc) score 8 is widely used in most guidelines for stroke prevention in patients with AF, with oral anticoagulants (OACs) being generally recommended for those with a CHA 2 DS 2 -VASc score $ 2. 9 Lifelong OAC therapy to prevent stroke is recommended, however, in patients with HCM who develop AF regardless of the patient's CHA 2 DS 2 -VASc score. [9] [10] [11] Non-vitamin K antagonist OACs (NOACs) may be reasonable alternatives to warfarin, but there are limited data to support their use because few patients with HCM were included in existing NOAC trials. 11, 12 Large observational studies may therefore offer an opportunity to examine the effectiveness and safety outcomes of NOAC use in these patients. In this nationwide cohort study, we sought to describe the pattern of use, occurrence of thromboembolic events and bleeding, and mortality in patients with HCM and AF treated with NOACs.
Materials and Methods
This study is based on the national health claims database established by the National Health Insurance Service (NHIS) of the Republic of Korea. 2, 3, 13 Details of Korean NHIS database are summarized in eAppendix 1. This study was approved by the institutional review board of the Yonsei University Health System (4-2016-0179), and informed consent was waived.
Study Population
From the Korean NHIS database, 10,020 patients with HCM and AF who were aged 18 years or older were identified during the period from January 1, 2011, to December 31, 2016. The following were exclusion criteria: (1) those with valvular AF, such as mitral valve stenosis or prosthetic valve disease (n ¼ 576); (2) those who had undergone radiofrequency ablation for AF (n ¼ 239); (3) those with end-stage renal disease (n ¼ 97); (4) those with no OAC use during the study period (January 1, 2011, to December 31, 2016) (n ¼ 3,667); (5) those with OAC use <30 days (n ¼ 1,821); and (6) those with OAC use for acute coronary syndrome or DVT prophylaxis (n ¼ 130). Finally, a total of 3,490 patients who took warfarin (n ¼ 1,188) or NOACs (n ¼ 2,302) were enrolled (Fig 1) . After propensity score (PS) matching, we identified a warfarin-treated group of patients with HCM and AF (n ¼ 955) who were compared with a 1:2 propensity-matched NOAC-treated group (n ¼ 1,504).
AF was diagnosed using the International Classification of Disease, 10th Revision (ICD-10) codes I48, I48.0, and I48.1. Moreover, patients were defined as having AF only when they were given AF as a discharge diagnosis, or when this diagnosis was confirmed more than twice in the outpatient department, to ensure diagnostic accuracy. ICD-10 codes were used when diagnosing HCM (I42.1, I42.2) and obstructive HCM (I42.1). The validation of AF and HCM diagnosis is summarized in e-Appendix 1.
Baseline Comorbidities and Outcome Events
Comorbidities were defined according to ICD-10 codes; prescription medication use was gathered using medical claim records. The definitions of comorbidities are presented in e- Table 1 . The presence of comorbidities was assessed at the time of OAC initiation.
Primary outcome events were the first occurrence of all-cause death, any ischemic stroke, major bleeding, and any acute myocardial infarction (MI). Secondary outcome events were the occurrence of fatal ischemic stroke, fatal bleeding, fatal acute MI, and the composite of these fatal cardiovascular events. Any event that led to death within 1 month of its occurrence was considered a fatal event. Detailed information on outcomes is summarized in e-Appendix 1.
Statistical Analysis
The detailed methods of statistical analysis are described in e-Appendix 1.
Results
Within the NOAC group (n ¼ 2,302), 890 patients were receiving rivaroxaban (38.7%), 705 dabigatran (30.6%), 585 apixaban (25.4%), and 122 edoxaban (5.3%). Table 1 shows the baseline characteristics of the study population before and after PS matching. Before PS matching, 55% of the NOAC group were men (vs 57% in the warfarin group; P ¼ .32) and the mean age was higher in the NOAC group compared with the warfarin group (70.9 AE 10.2 vs 67.0 AE 12.5 years; P < .001). All comorbidities, including previous transient ischemic attack/ischemic stroke, hemorrhagic stroke, atherosclerotic disease, hypertension, diabetes, heart failure, malignant neoplasm, chronic kidney disease, dyslipidemia and COPD, were more prevalent in patients on NOACs than in those on warfarin (all P < .05). e- Table 2 shows that the baseline medications were also different between the two groups, with a higher use of antiplatelet therapy (aspirin or P2Y12 inhibitor) in the warfarin group (all P < .05). Covariates had significant imbalances in the prematched cohort but were well balanced after PS matching. Absolute standardized mean differences in all measured covariates were < 0.1, suggesting substantial covariate balance across the groups after PS matching.
Primary Outcome Events
During a median follow-up of 16 months (interquartile range, 8-24 months), when considering the NOAC and warfarin groups together before PS matching, ischemic stroke/systemic embolism and major bleeding occurred in 9.7% (339 of 3,490) and 6.3% (219 of 3,490) of patients with AF and HCM, respectively. Overall, 315 of 3,490 patients (9.0%) died (e- Table 3 ).
In the PS-matched groups, the incidence rates for ischemic stroke or systemic embolism were similar between NOAC-and warfarin-treated patients (8.33 vs 7.96 events per 100 person-years, respectively; P ¼ .725) (Fig 2) . Rates of major bleeding, GI bleeding, intracranial hemorrhage, and acute MI were also similar between NOAC-and warfarin-treated patients. The incidence rate for all-cause death was significantly lower in NOAC-treated than in warfarin-treated patients (5.11 vs 10.13 events per 100 person-years, respectively; P < .001). Compared with warfarin, use of NOACs was associated with a significantly lower risk of all causemortality (hazard ratio [HR]) of 0.43 (95% CI, 0.32-0.57; P < .001) (Fig 2) . Both standard-dose (HR, 0.40; 95% CI, 0.27-0.60) and reduced-dose NOACs (HR, 0.45; 95% CI, 0.32-0.63) were associated with significantly lower risk of all-cause mortality with reference to warfarin (e- Table 4 ). Figure 3 shows the Kaplan-Meier curves for clinical events in NOAC-and warfarin-treated patients after PS matching. NOAC use was associated with significantly better event-free survival from all-cause death than warfarin-treated patients (log-rank P < .001).
Secondary Outcome Events
We compared the fatal cardiovascular events between PS-matched NOAC-and warfarin-treated patients. The incidence rates of fatal ischemic stroke (0.40 vs 0.48 events per 100 person-years, respectively; HR, 0.87; 95% CI, 0.25-2.98; P ¼ .819) were similar between NOAC-and warfarin-treated patients; however, use of NOACs was associated with lower risks of fatal bleeding (0.33 vs 1.02 events per 100 person-years, respectively; HR, 0.33; 95% CI, 0.11-0.99; P ¼ .047) and fatal MI (0.06 vs 0.39 events per 100 person-years, respectively; HR, 0.06; 95% CI, 0.00-0.92; P ¼ .043) compared with warfarin-treated patients. Consequentially, the incidence rate for the composite of these fatal cardiovascular events was significantly lower in NOAC-treated patients compared with warfarin-treated patients (0.77 vs 1.80 events per 100 person-years, respectively; HR, 0.39; 95% CI, 0.18-0.82; P ¼ .013) (Fig 4) . Similar results were observed after propensity score matching for comorbidities and usage of aspirin and P2Y12 inhibitors (e-Figs 1, 2). Figure 5 shows the Kaplan-Meier curves for fatal clinical events in NOAC-treated and warfarin-treated patients. NOAC was associated with significantly better eventfree survival from fatal bleeding (log-rank P ¼ .023), fatal MI (log-rank P ¼ .037) and composite fatal cardiovascular events (log-rank P ¼ .010) than warfarin.
Subgroup Analysis
The mortality benefit of NOACs compared with warfarin in patients with AF and HCM was consistent across most subgroups, although it could not be assessed in patients with CHA 2 DS 2 -VASc scores # 1 or in those without hypertension because of the small number of subjects (Fig 6) . Compared with warfarin, use of NOAC was associated with significantly lower risk of all-cause mortality, regardless of sex, heart failure, diabetes mellitus, previous transient ischemic attack/ischemic stroke, and chronic kidney disease. NOACs were associated with a significantly lower all-cause mortality than warfarin in those aged $ 65 years, those without previous MI, those with dyslipidemia, those with nonobstructive HCM, those with CHA 2 DS 2 -VASc score $ 2, and those with hypertension.
There was no significant difference in the number of events, incidence, and risk of various events among apixaban, dabigatran, and rivaroxaban in patients with AF and HCM (e- Table 5 ).
Discussion
The principal finding of this study was that the incidences of stroke or major bleeding were similar between NOACand warfarin-treated patients with AF and HCM. Second, use of NOAC was associated with significantly lower allcause mortality than warfarin; moreover, the composite of fatal cardiovascular events was lower among NOACtreated patients compared with warfarin-treated patients.
The lower all-cause mortality in NOAC-treated patients was evident across most subgroups. Our data suggest that patients with AF and HCM can be safely and effectively treated with NOACs.
OACs for Patients With AF and HCM
AF is the most common arrhythmia in patients with HCM. Prospective data show that after 10 years of follow-up, 22% to 30% of patient with HCM develop AF. 4, 5, 14 AF has a strong effect on the clinical course of HCM and on patients' quality of life. Because of the very high embolic risk, life-long OAC treatment is recommended in all patients with HCM and AF. This recommendation is made on the basis of observational studies showing that warfarin-treated patients with HCM and AF presented with about one-half the number of embolic events (18% vs 31%, respectively) and strokes (10% vs 39%, respectively) compared with those not receiving OAC treatment. 4 Although patients with HCM were not formally excluded from NOAC trials, the number of patients with HCM included in these studies is unknown and 
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No. at risk Warfarin NOAC Log-rank P = .221 chestjournal.org was presumably low because they tend to be younger (the mean age of patients included in NOAC trials was > 70 years) and often do not exhibit the traditional CHADS 2 factors required to participate in NOAC studies. Few data therefore currently support the use of NOACs in patients with HCM and AF despite the notion that NOACs could represent a valid alternative to warfarin treatment in this younger, active population.
Myocardial Infarction
The latest guidelines state that NOACs are broadly preferable to warfarin in the vast majority of patients with nonvalvular AF 9 and are made on the basis of clinical trials that have shown equivalent efficacy compared with warfarin as well as better safety and a lower occurrence of intracranial hemorrhage. 15 Furthermore, studies have observed that NOACs are more cost effective than adjusted-dose warfarin 16 and that patients with nonvalvular AF are generally more satisfied with medical care when treated with NOACs.
Because this study only included HCM patients with AF on OACs, it is impossible to directly compare the prevalence of comorbidities and incidence of outcome events with other studies which included overall patients with HCM. The high prevalence of comorbidities, including hypertension and heart failure in HCM with OAC, may be related with the fact that this study only included HCM patients with AF receiving OACs. Although the prevalence of hypertension was above 90% in this study, it was only 68% in HCM patients without AF (e- Table 6 ). The comparison of other comorbidities and outcome events with other studies is further discussed in e-Appendix 2.
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. The annual rates of ischemic stroke, systemic embolism, or major bleeding were similar between NOAC-and warfarin-treated patients. Our data show that usage of NOACs was associated with significantly lower all-cause mortality compared with warfarin, especially by reducing the composite of fatal cardiovascular events. In prior randomized clinical trials of NOAC vs warfarin, there was no reduction in mortality except in apixaban trial. In Danish nationwide databases, however, the annual risk of death was significantly lower with apixaban and dabigatran compared with warfarin. 17 In real-world data from Asian patients with nonvalvular AF, NOACs were associated with reduced risk for all-cause mortality compared with warfarin. 18 This finding was well explained by lower risk of composite of fatal cardiovascular events associated with NOAC use in this study.
Studies have suggested that patients with HCM and AF could be safely treated with NOACs 12, 19 ; however, these studies were likely underpowered in terms of the number of individuals needed to concretely demonstrate the superiority of NOACs over warfarin in patients with HCM and AF. The results of our study, which used the largest sample of subjects with HCM published thus far, favor the use of NOACs as an alternative to warfarin when OAC treatment is needed for patients with HCM and AF.
In the subgroup analyses, the mortality reduction associated with NOAC treatment was observed across most subgroups. The prevalence of hypertension was > 95% in both PS-matched NOAC-and warfarintreated groups. Because NOAC treatment is fully reimbursed in Korean patients with AF and CHA 2 DS 2 -VASc scores $ 2 only, the number of patients using NOACs was low among those with CHA 2 DS 2 -VASc scores # 1. The benefit of NOAC treatment therefore was not adequately assessed in patients with CHA 2 DS 2 -VASc scores # 1 or in those without hypertension.
Major and GI bleeding was more prevalent in reduceddose NOAC than standard-dose users. This finding is consistent with previous studies. 20, 21 In real-world studies, the choice of dosage of NOAC was obviously not from random chance, but rather a complex mixture of physician experience, patient preferences, and clinical characteristics.
Study Limitations
The present study has several limitations. Although administrative databases are increasingly used for clinical research, studies using such databases are potentially susceptible to errors arising from coding inaccuracies. To minimize this problem, we applied the definitions that we had already validated in previous studies that used a Korean NHIS sample cohort. 2, 3, 22 Although we validated the accuracy of our definition of HCM, we cannot exclude the possibility that hypertensive heart disease was included in our study population. Second, we were unable to define the type of AF (paroxysmal vs persistent) in this study. In addition, we relied on billing codes for determination of patient characteristics and outcomes. As such, we lacked data on clinical characteristics, such as mitral valve dysfunction, left atrial enlargement, left ventricular dysfunction, and other factors that may predispose patients to cardioembolism. The information on family history of HCM and of sudden death was also unavailable. Third, more than one-half the NOAC-treated patients in this study were receiving reduced doses of NOACs. This finding is consistent with the previous study that Asian physicians tend to prescribe low-dose NOACs to patients with AF for a number of reasons, including the lower average BMI of Asian adults and the concern for higher risk of intracerebral hemorrhage. 23 Finally, we had no data on time in therapeutic range (TTR) for the warfarin group because of the limitations of the national health claim database. Poor TTR status has generally been observed in Asian cohorts, 24, 25 and may have affected the favorable mortality outcomes seen in the NOAC group. A single-center study in which warfarin therapy was managed by a formal anticoagulation clinic showed that the TTR in patients with AF-related stroke was 57.5%. 26 A multicenter retrospective study reported that the mean TTR of individual patients was 49.1% in Korean patients with AF. 27 Nonetheless, these observational data provide a glimpse of real-world clinical outcomes associated with NOAC use in patients with HCM and AF, a group not well studied in previously published or ongoing clinical trials.
Conclusions
Compared with those on warfarin, patients with AF and HCM on NOACs had similar stroke and major bleeding risks, but were associated with lower all-cause mortality and the composite of fatal cardiovascular events. Our data suggest that patients with HCM and AF can be safely and effectively treated with NOACs.
